Sep 14, 2026•3 min read
Oncogenic Therapeutics launches Phase 3 trial of Zaqibo (Jastafrazan) for H. pylori eradication
Oncogenic Therapeutics secured MFDS approval for a Phase 3 study of its P‑CAB drug Zaqibo to treat Helicobacter pylori infection in 414 patients across 24 Korean sites.